_id
695fb6ddc2e91020a7bd422b
Ticker
0HL9.LSE
Name
Affimed N.V.
Exchange
LSE
Address
Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165
Country
UK
Sector
Industry
Currency
USD
Website
https://www.affimed.com
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Last Close
0.0001
Volume
420
Current Price
0.0001
Last Updated
2026-01-08T13:53:33.309Z
Ipo Date
-
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2024-09-30
Revenue
155000
Cost Of Revenue
-
Gross Profit
155000
Operating Expenses
14438000
Operating Income
-14283000
Interest Expense
267000
Pretax Income
-15138000
Net Income
-15139000
Eps
-0.9402997543195932
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
1000
EBITDA
-14446000
Operating Margin
-9214.838709677419
Total Other Income Expense Net
-855000
Cash
7405000
Short Term Investments
17535000
Receivables
4543000
Inventories
-
Total Current Assets
32391000
Property Plant Equipment
7553000
Total Assets
39959000
Payables
9256000
Short Term Debt
6903000
Long Term Debt
-
Total Liabilities
22764000
Equity
17195000
Bs_currency_symbol
-
Depreciation
425000
Change In Working Capital
2322000
Cash From Operations
-11135000
Capital Expenditures
5000
Cash From Investing
6667000
Cash From Financing
1296000
Net Change In Cash
-3359000
Cf_currency_symbol
-
PE
-
PB
0.00009363294562372783
ROE
-88.0430357662111
ROA
-37.88633349182913
FCF
-11140000
Fcf Percent
-71.87096774193549
Piotroski FScore
1
Health Score
24
Deep Value Investing Score
3
Defensive Investing Score
6
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1.5
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
1.5
Quality Investing Score
1.5
Value Investing Score
4
Quarters > 0 > quarter
2024-09-30
Quarters > 0 > income Statement > revenue
155000
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
155000
Quarters > 0 > income Statement > operating Expenses
14438000
Quarters > 0 > income Statement > operating Income
-14283000
Quarters > 0 > income Statement > interest Expense
267000
Quarters > 0 > income Statement > pretax Income
-15138000
Quarters > 0 > income Statement > net Income
-15139000
Quarters > 0 > income Statement > eps
-0.9402997543195932
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
16100185
Quarters > 0 > income Statement > income Tax Expense
1000
Quarters > 0 > income Statement > EBITDA
-14446000
Quarters > 0 > income Statement > operating Margin
-9214.838709677419
Quarters > 0 > income Statement > total Other Income Expense Net
-855000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
7405000
Quarters > 0 > balance Sheet > short Term Investments
17535000
Quarters > 0 > balance Sheet > receivables
4543000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
32391000
Quarters > 0 > balance Sheet > property Plant Equipment
7553000
Quarters > 0 > balance Sheet > total Assets
39959000
Quarters > 0 > balance Sheet > payables
9256000
Quarters > 0 > balance Sheet > short Term Debt
6903000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
22764000
Quarters > 0 > balance Sheet > equity
17195000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-15139000
Quarters > 0 > cash Flow > depreciation
425000
Quarters > 0 > cash Flow > change In Working Capital
2322000
Quarters > 0 > cash Flow > cash From Operations
-11135000
Quarters > 0 > cash Flow > capital Expenditures
5000
Quarters > 0 > cash Flow > cash From Investing
6667000
Quarters > 0 > cash Flow > cash From Financing
1296000
Quarters > 0 > cash Flow > net Change In Cash
-3359000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.9402997543195932
Quarters > 0 > ratios > PB
0.00009363294562372783
Quarters > 0 > ratios > ROE
-88.0430357662111
Quarters > 0 > ratios > ROA
-37.88633349182913
Quarters > 0 > ratios > FCF
-11140000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-71.87096774193549
Quarters > 0 > health Score
24
Quarters > 1 > quarter
2024-06-30
Quarters > 1 > income Statement > revenue
154000
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
154000
Quarters > 1 > income Statement > operating Expenses
15707000
Quarters > 1 > income Statement > operating Income
-15553000
Quarters > 1 > income Statement > interest Expense
316000
Quarters > 1 > income Statement > pretax Income
-15448000
Quarters > 1 > income Statement > net Income
-15451000
Quarters > 1 > income Statement > eps
-1.0098090885040054
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
15300912
Quarters > 1 > income Statement > income Tax Expense
3000
Quarters > 1 > income Statement > EBITDA
-14702000
Quarters > 1 > income Statement > operating Margin
-10099.350649350648
Quarters > 1 > income Statement > total Other Income Expense Net
105000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
10764000
Quarters > 1 > balance Sheet > short Term Investments
24561000
Quarters > 1 > balance Sheet > receivables
5717000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
45187000
Quarters > 1 > balance Sheet > property Plant Equipment
7969000
Quarters > 1 > balance Sheet > total Assets
53174000
Quarters > 1 > balance Sheet > payables
9171000
Quarters > 1 > balance Sheet > short Term Debt
6882000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
24460000
Quarters > 1 > balance Sheet > equity
28714000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-15451000
Quarters > 1 > cash Flow > depreciation
430000
Quarters > 1 > cash Flow > change In Working Capital
-1745000
Quarters > 1 > cash Flow > cash From Operations
-16509000
Quarters > 1 > cash Flow > capital Expenditures
19000
Quarters > 1 > cash Flow > cash From Investing
11606000
Quarters > 1 > cash Flow > cash From Financing
1231000
Quarters > 1 > cash Flow > net Change In Cash
-3584000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-1.0098090885040054
Quarters > 1 > ratios > PB
0.000053287288430730654
Quarters > 1 > ratios > ROE
-53.80998815908617
Quarters > 1 > ratios > ROA
-29.05743408432693
Quarters > 1 > ratios > FCF
-16528000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-107.32467532467533
Quarters > 1 > health Score
29
Quarters > 2 > quarter
2024-03-31
Quarters > 2 > income Statement > revenue
155000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
155000
Quarters > 2 > income Statement > operating Expenses
19867000
Quarters > 2 > income Statement > operating Income
-19535000
Quarters > 2 > income Statement > interest Expense
363000
Quarters > 2 > income Statement > pretax Income
-19175000
Quarters > 2 > income Statement > net Income
-19175000
Quarters > 2 > income Statement > eps
-1.2673536571695667
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
15129952
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-16722000
Quarters > 2 > income Statement > operating Margin
-12603.225806451614
Quarters > 2 > income Statement > total Other Income Expense Net
360000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
14348000
Quarters > 2 > balance Sheet > short Term Investments
35027000
Quarters > 2 > balance Sheet > receivables
6038000
Quarters > 2 > balance Sheet > inventories
700000
Quarters > 2 > balance Sheet > total Current Assets
62157000
Quarters > 2 > balance Sheet > property Plant Equipment
8374000
Quarters > 2 > balance Sheet > total Assets
70553000
Quarters > 2 > balance Sheet > payables
12891000
Quarters > 2 > balance Sheet > short Term Debt
6805000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
29890000
Quarters > 2 > balance Sheet > equity
40663000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-19175000
Quarters > 2 > cash Flow > depreciation
2090000
Quarters > 2 > cash Flow > change In Working Capital
-7422000
Quarters > 2 > cash Flow > cash From Operations
-23818000
Quarters > 2 > cash Flow > capital Expenditures
1000
Quarters > 2 > cash Flow > cash From Investing
-1000
Quarters > 2 > cash Flow > cash From Financing
-417000
Quarters > 2 > cash Flow > net Change In Cash
-24181000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-1.2673536571695667
Quarters > 2 > ratios > PB
0.00003720815483363254
Quarters > 2 > ratios > ROE
-47.15589110493569
Quarters > 2 > ratios > ROA
-27.178149759755076
Quarters > 2 > ratios > FCF
-23819000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-153.67096774193547
Quarters > 2 > health Score
29
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
413000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
413000
Quarters > 3 > income Statement > operating Expenses
24604000
Quarters > 3 > income Statement > operating Income
-20835000
Quarters > 3 > income Statement > interest Expense
412000
Quarters > 3 > income Statement > pretax Income
-20205000
Quarters > 3 > income Statement > net Income
-20205000
Quarters > 3 > income Statement > eps
-1.3524172425065843
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
14939916
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-19317000
Quarters > 3 > income Statement > operating Margin
-5044.794188861985
Quarters > 3 > income Statement > total Other Income Expense Net
630000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
38529000
Quarters > 3 > balance Sheet > short Term Investments
34369000
Quarters > 3 > balance Sheet > receivables
5327000
Quarters > 3 > balance Sheet > inventories
463000
Quarters > 3 > balance Sheet > total Current Assets
84188000
Quarters > 3 > balance Sheet > property Plant Equipment
12944000
Quarters > 3 > balance Sheet > total Assets
97157000
Quarters > 3 > balance Sheet > payables
18916000
Quarters > 3 > balance Sheet > short Term Debt
6372000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
39350000
Quarters > 3 > balance Sheet > equity
57807000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-20205000
Quarters > 3 > cash Flow > depreciation
476000
Quarters > 3 > cash Flow > change In Working Capital
-2150000
Quarters > 3 > cash Flow > cash From Operations
-25442000
Quarters > 3 > cash Flow > capital Expenditures
509000
Quarters > 3 > cash Flow > cash From Investing
1407000
Quarters > 3 > cash Flow > cash From Financing
-1396000
Quarters > 3 > cash Flow > net Change In Cash
-24288000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-1.3524172425065843
Quarters > 3 > ratios > PB
0.000025844475582541906
Quarters > 3 > ratios > ROE
-34.952514401370074
Quarters > 3 > ratios > ROA
-20.79623701843408
Quarters > 3 > ratios > FCF
-25951000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-62.83535108958838
Quarters > 3 > health Score
29
Annuals > 0 > quarter
2023-12-31
Annuals > 0 > income Statement > revenue
8275000
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
8275000
Annuals > 0 > income Statement > operating Expenses
114936000
Annuals > 0 > income Statement > operating Income
-106661000
Annuals > 0 > income Statement > interest Expense
1806000
Annuals > 0 > income Statement > pretax Income
-105935000
Annuals > 0 > income Statement > net Income
-105938000
Annuals > 0 > income Statement > eps
-7.0909367897383095
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
14939916
Annuals > 0 > income Statement > income Tax Expense
3000
Annuals > 0 > income Statement > EBITDA
-102380000
Annuals > 0 > income Statement > operating Margin
-1288.954682779456
Annuals > 0 > income Statement > total Other Income Expense Net
726000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
38529000
Annuals > 0 > balance Sheet > short Term Investments
34369000
Annuals > 0 > balance Sheet > receivables
5327000
Annuals > 0 > balance Sheet > inventories
463000
Annuals > 0 > balance Sheet > total Current Assets
84188000
Annuals > 0 > balance Sheet > property Plant Equipment
12944000
Annuals > 0 > balance Sheet > total Assets
97157000
Annuals > 0 > balance Sheet > payables
18916000
Annuals > 0 > balance Sheet > short Term Debt
6372000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
39350000
Annuals > 0 > balance Sheet > equity
57807000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-105938000
Annuals > 0 > cash Flow > depreciation
1749000
Annuals > 0 > cash Flow > change In Working Capital
-12161000
Annuals > 0 > cash Flow > cash From Operations
-110269000
Annuals > 0 > cash Flow > capital Expenditures
3729000
Annuals > 0 > cash Flow > cash From Investing
-36059000
Annuals > 0 > cash Flow > cash From Financing
-6220000
Annuals > 0 > cash Flow > net Change In Cash
-151757000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-7.0909367897383095
Annuals > 0 > ratios > PB
0.000025844475582541906
Annuals > 0 > ratios > ROE
-183.26154271973982
Annuals > 0 > ratios > ROA
-109.03794888685323
Annuals > 0 > ratios > FCF
-113998000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-13.776193353474321
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2022-12-31
Annuals > 1 > income Statement > revenue
41353000
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
41353000
Annuals > 1 > income Statement > operating Expenses
130889000
Annuals > 1 > income Statement > operating Income
-88119000
Annuals > 1 > income Statement > interest Expense
1630000
Annuals > 1 > income Statement > pretax Income
-86002000
Annuals > 1 > income Statement > net Income
-86004000
Annuals > 1 > income Statement > eps
-6.041206558281691
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
14236229
Annuals > 1 > income Statement > income Tax Expense
2000
Annuals > 1 > income Statement > EBITDA
-81473000
Annuals > 1 > income Statement > operating Margin
-213.08973955940317
Annuals > 1 > income Statement > total Other Income Expense Net
2117000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
190286000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
2697000
Annuals > 1 > balance Sheet > inventories
628000
Annuals > 1 > balance Sheet > total Current Assets
196070000
Annuals > 1 > balance Sheet > property Plant Equipment
4384000
Annuals > 1 > balance Sheet > total Assets
200512000
Annuals > 1 > balance Sheet > payables
19077000
Annuals > 1 > balance Sheet > short Term Debt
6326000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
47597000
Annuals > 1 > balance Sheet > equity
152915000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-86004000
Annuals > 1 > cash Flow > depreciation
2899000
Annuals > 1 > cash Flow > change In Working Capital
-38067000
Annuals > 1 > cash Flow > cash From Operations
-104892000
Annuals > 1 > cash Flow > capital Expenditures
696000
Annuals > 1 > cash Flow > cash From Investing
5605000
Annuals > 1 > cash Flow > cash From Financing
88557000
Annuals > 1 > cash Flow > net Change In Cash
-7344000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-6.041206558281691
Annuals > 1 > ratios > PB
0.000009309897001602197
Annuals > 1 > ratios > ROE
-56.243010823006244
Annuals > 1 > ratios > ROA
-42.89219597829556
Annuals > 1 > ratios > FCF
-105588000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-2.5533334945469495
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2021-12-31
Annuals > 2 > income Statement > revenue
40366000
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
40366000
Annuals > 2 > income Statement > operating Expenses
105706000
Annuals > 2 > income Statement > operating Income
-64030000
Annuals > 2 > income Statement > interest Expense
712000
Annuals > 2 > income Statement > pretax Income
-57521000
Annuals > 2 > income Statement > net Income
-57523000
Annuals > 2 > income Statement > eps
-4.813544299285085
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
11950238
Annuals > 2 > income Statement > income Tax Expense
2000
Annuals > 2 > income Statement > EBITDA
-55421787
Annuals > 2 > income Statement > operating Margin
-158.6235941138582
Annuals > 2 > income Statement > total Other Income Expense Net
6509000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
197630000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
4809000
Annuals > 2 > balance Sheet > inventories
421000
Annuals > 2 > balance Sheet > total Current Assets
206394000
Annuals > 2 > balance Sheet > property Plant Equipment
4786000
Annuals > 2 > balance Sheet > total Assets
225135000
Annuals > 2 > balance Sheet > payables
18860000
Annuals > 2 > balance Sheet > short Term Debt
1263000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
89184000
Annuals > 2 > balance Sheet > equity
135951000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-57523000
Annuals > 2 > cash Flow > depreciation
1334000
Annuals > 2 > cash Flow > change In Working Capital
-34808000
Annuals > 2 > cash Flow > cash From Operations
-86591000
Annuals > 2 > cash Flow > capital Expenditures
3850000
Annuals > 2 > cash Flow > cash From Investing
-3850000
Annuals > 2 > cash Flow > cash From Financing
133581000
Annuals > 2 > cash Flow > net Change In Cash
50776000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-4.813544299285085
Annuals > 2 > ratios > PB
0.000008790106729630529
Annuals > 2 > ratios > ROE
-42.31156813852049
Annuals > 2 > ratios > ROA
-25.550447509272217
Annuals > 2 > ratios > FCF
-90441000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-2.2405242035376305
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2020-12-31
Annuals > 3 > income Statement > revenue
28360000
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
28360000
Annuals > 3 > income Statement > operating Expenses
63704000
Annuals > 3 > income Statement > operating Income
-34718000
Annuals > 3 > income Statement > interest Expense
95000
Annuals > 3 > income Statement > pretax Income
-41365000
Annuals > 3 > income Statement > net Income
-41366000
Annuals > 3 > income Statement > eps
-4.955699881492571
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
8347156
Annuals > 3 > income Statement > income Tax Expense
1000
Annuals > 3 > income Statement > EBITDA
-40231161
Annuals > 3 > income Statement > operating Margin
-122.41889985895628
Annuals > 3 > income Statement > total Other Income Expense Net
-6647000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
146854000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
2439000
Annuals > 3 > balance Sheet > inventories
246000
Annuals > 3 > balance Sheet > total Current Assets
150799000
Annuals > 3 > balance Sheet > property Plant Equipment
3166000
Annuals > 3 > balance Sheet > total Assets
175725000
Annuals > 3 > balance Sheet > payables
11394000
Annuals > 3 > balance Sheet > short Term Debt
584000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
103732000
Annuals > 3 > balance Sheet > equity
71993000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-41366000
Annuals > 3 > cash Flow > depreciation
1115000
Annuals > 3 > cash Flow > change In Working Capital
10573000
Annuals > 3 > cash Flow > cash From Operations
-19400000
Annuals > 3 > cash Flow > capital Expenditures
440000
Annuals > 3 > cash Flow > cash From Investing
8006000
Annuals > 3 > cash Flow > cash From Financing
69252000
Annuals > 3 > cash Flow > net Change In Cash
51620000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-4.955699881492571
Annuals > 3 > ratios > PB
0.000011594399455502619
Annuals > 3 > ratios > ROE
-57.45836400761185
Annuals > 3 > ratios > ROA
-23.54019063878219
Annuals > 3 > ratios > FCF
-19840000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-0.6995768688293371
Annuals > 3 > health Score
23
Valuation > metrics > PE
-0.9402997543195932
Valuation > metrics > PB
0.00009363294562372783
Valuation > final Score
70
Valuation > verdict
100.0% Undervalued
Profitability > metrics > ROE
-88.0430357662111
Profitability > metrics > ROA
-46.73829150072551
Profitability > metrics > Net Margin
-97.67096774193548
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.3238732189589997
Risk > metrics > Interest Coverage
-53.49438202247191
Risk > final Score
-184
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.004517606287518
Liquidity > metrics > Quick Ratio
2.004517606287518
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-149
Prev Risks > 1
-167
Prev Risks > 2
-154
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:30.904Z
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2024-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Affimed N.V.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2024-09-30)
(Last Updated 2024-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2024-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2024-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.